- Home
- PCRX vs MLKN Comparison
PCRX vs MLKN Comparison
Compare PCRX & MLKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- MLKN
- Stock Information
- Founded
- PCRX 2006
- MLKN 1905
- Country
- PCRX United States
- MLKN United States
- Employees
- PCRX N/A
- MLKN N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- MLKN Office Equipment/Supplies/Services
- Sector
- PCRX Health Care
- MLKN Consumer Discretionary
- Exchange
- PCRX Nasdaq
- MLKN Nasdaq
- Market Cap
- PCRX 1.2B
- MLKN 1.2B
- IPO Year
- PCRX 2011
- MLKN N/A
- Fundamental
- Price
- PCRX $23.96
- MLKN $16.11
- Analyst Decision
- PCRX Strong Buy
- MLKN
- Analyst Count
- PCRX 6
- MLKN 0
- Target Price
- PCRX $33.83
- MLKN N/A
- AVG Volume (30 Days)
- PCRX 769.6K
- MLKN 1.2M
- Earning Date
- PCRX 11-06-2025
- MLKN 12-17-2025
- Dividend Yield
- PCRX N/A
- MLKN 4.71%
- EPS Growth
- PCRX N/A
- MLKN N/A
- EPS
- PCRX 0.47
- MLKN N/A
- Revenue
- PCRX $716,791,000.00
- MLKN $3,764,100,000.00
- Revenue This Year
- PCRX $7.27
- MLKN $5.40
- Revenue Next Year
- PCRX $10.18
- MLKN $3.96
- P/E Ratio
- PCRX $50.52
- MLKN N/A
- Revenue Growth
- PCRX 3.14
- MLKN 5.37
- 52 Week Low
- PCRX $16.29
- MLKN $13.77
- 52 Week High
- PCRX $27.64
- MLKN $25.96
- Technical
- Relative Strength Index (RSI)
- PCRX 56.14
- MLKN 57.56
- Support Level
- PCRX $22.29
- MLKN $13.77
- Resistance Level
- PCRX $24.95
- MLKN $15.53
- Average True Range (ATR)
- PCRX 1.23
- MLKN 0.58
- MACD
- PCRX 0.09
- MLKN 0.29
- Stochastic Oscillator
- PCRX 78.19
- MLKN 96.68
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About MLKN MillerKnoll Inc.
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.